BMSN - Bio-Matrix Scientific Group - WKN: A0NJL3 - Seite 2

TankerOne · 02-03-2013, 22:46

BMSN $ NEWS - BMSN will shoot over 0,10 after FDA Approval $$$

sierraworldequityreview.blogspot.de/2013/03/new-price-targetbio-matrix-scientific_2.html?m=1

$$$ Alert__BREAKING>>>>Biotech News Stock Review Breaks It First!_Approval Granted_Bio-Matrix Scientific Group (BMSN) Sails Through FDA Investigational New Drug (IND) Process, Next Orphan Drug Designation Predicts Biotech News Stock Review
Biotech News Stock Review Breaks It First!_Approval Granted_Bio-Matrix Scientific Group (BMSN) Sails Through FDA Investigational New Drug (IND) Process, Next Orphan Drug Designation Predicts Biotech News Stock Review.

Sierra World Equity Review

Saturday, March 2, 2013
New Price Target_Bio-Matrix Scientific Group (BMSN) To Run To 10 Cents Following Upcoming FDA Approval To Move Forward With HemaXellerate Predicts Sierra World Equity Review. That's Just The Tip Of The Iceberg, Dollarland Coming Upon Orphan Drug Designation Forecasts Sierra World Equity Review
HEADLINE: New Price Target_Bio-Matrix Scientific Group (BMSN) To Run To 10 Cents Following Upcoming FDA Approval To Move Forward With HemaXellerate Predicts Sierra World Equity Review. That's Just The Tip Of The Iceberg, Dollarland Coming Upon Orphan Drug Designation Forecasts Sierra World Equity Review.

For the latest updates on these stocks and to learn more about Sierra go to:

Sierra's Hot Stock Website
2013 FDA Calender
Latest Clinical Trial Results

A list of all Sierra's accurate calls and predictions that came true:
All These Came True, Accurate Sierra Are You Believer Yet!!!

Accurate call after accurate call, smart, single supermodel Sierra is SMOKING HOT in her predictions!! From FDA Drug Approvals and Trials to Potential Joint Ventures, Mergers, Buyouts, Acquisitions and Lawsuit Settlements..... get THE Scoop, always on the cutting edge of BIG Breaking News. Sierra covers all sectors from Biotech to Oil stocks, Gold stocks, Penny stocks on the OTC as well as the S&P, Nasdaq, Dow Jones and Amex. Famous for her HEADLINERS, Sierra made more correct calls in the last 9 months than all other Stock Reviews COMBINED.
Check back for instant updates....Independent Sierra World Equity Review currently hold no positions in any of the stocks listed above......be the first to read Sierra's new posts, follow Sierra on Twitter
Sierra World Equity Review at 1:02 AM

BMSN $ STRONG BUY $ Target: 1,00+ US Dollars

< Message edited by Bullrider77 -- 3/2/2013 3:40:26 PM >

TankerOne · 04-03-2013, 00:30

BMSN. BMSN. BMSN. NEWS. NEWS. NEWS. Big big NEWS. Soon. IMO. http://www.regenbiopharma.com/news-events.html BMSN. http://www.regenbiopharma.com/index.html. BMSN. BMSN. BMSN.

TankerOne · 05-03-2013, 17:50

BMSN - FDA NEWS SOON $ Strong Buy $$$

TankerOne · 06-03-2013, 01:13

http://regenbiopharma.com/pdf/regen-...e-4-30-201.pdf

BMSN..BMSN..BMSN..
Penny Stock Experts Blog - blog.todayspickis.com: Stocks To Watch 03/06/13 - BMSN Penny Stock Experts Blog - blog.todayspickis.com: Stocks To Watch 03/06/13 - BMSN

BMSN - Momentum/Breakout Watch - (Bio-Matrix Scientific Group Inc.) - closed up 42.55%, at .0134c a share, on over 84.11 million shares traded today. Shares traded sideways this morning, before rallying up to .0138c a share, and closing slightly lower at .0134c. The stock showed impressive strength this afternoon which leads us to believe the stock could move higher into tomorrow and over the coming days. Look for a break and close above .015c to signal a further breakout. Keep it on close watch.

BMSN..BMSN..BMSN..BMSN..BMSN..

TankerOne · 06-03-2013, 10:27

ALERT

—FDA 2013 Calender and Clinical Trial Results—Latest Biotech News Stock Review Updates

Latest Biotech News Stock Review Calls and Forecasts:

March 5th, 2013

ALERT_Official Press Release Scheduled To Be Released By Bio-Matrix Scientific Group (BMSN) This Week_Massive Run Coming Predicts Biotech News Stock Review. Johnny is hearing that the PR is drawn up and ready to be released, when it happens remember we told you first!

http://www.biotechnewsstockreview.com/

TankerOne · 13-03-2013, 22:04

BMSN - NEWS $$$ FDA 2013 Calender and Clinical Trial Results $$$

—Alert__BREAKING>>>>Biotech News Stock Review Breaks It First!_Approval Granted_Bio-Matrix Scientific Group (BMSN) Sails Through FDA Investigational New Drug (IND) Process, Next Orphan Drug Designation Predicts Biotech News Stock Review
Biotech News Stock Review Breaks It First!_Approval Granted_Bio-Matrix Scientific Group (BMSN) Sails Through FDA Investigational New Drug (IND) Process, Next Orphan Drug Designation Predicts Biotech News Stock Review.

Johnny is hearing from his very reliable sources that the FDA is shortly going to release the good news that BMSN shareholders have been waiting for, APPROVAL for HemaXellerate to move on and proceed with clinical trials. Wait for official word and then enjoy the ride shareholders of BMSN, check back for more updates!
Biotech Stock Share Price Rise Or Fall Projections For Week Of February 25th To March 1st 2013

Target: 2,00 - 3,00 + Longtermtarget $$$ Dollars

Mit Zitat antworten Beitrag zum Zitieren auswählen Direkt antworten
BMSN - NEWS $$$ FDA 2013 Calender and Clinical Trial Results $$$ —Alert__BREAKING>>> Beitrag #2
BMSN $ NEWS - BMSN will shoot over 0,10 after FDA Approval $$$

sierraworldequityreview.blogspot.de/2013/03/new-price-targetbio-matrix-scientific_2.html?m=1

$$$ Alert__BREAKING>>>>Biotech News Stock Review Breaks It First!_Approval Granted_Bio-Matrix Scientific Group (BMSN) Sails Through FDA Investigational New Drug (IND) Process, Next Orphan Drug Designation Predicts Biotech News Stock Review
Biotech News Stock Review Breaks It First!_Approval Granted_Bio-Matrix Scientific Group (BMSN) Sails Through FDA Investigational New Drug (IND) Process, Next Orphan Drug Designation Predicts Biotech News Stock Review.

Sierra World Equity Review

Saturday, March 2, 2013
New Price Target_Bio-Matrix Scientific Group (BMSN) To Run To 10 Cents Following Upcoming FDA Approval To Move Forward With HemaXellerate Predicts Sierra World Equity Review. That's Just The Tip Of The Iceberg, Dollarland Coming Upon Orphan Drug Designation Forecasts Sierra World Equity Review
HEADLINE: New Price Target_Bio-Matrix Scientific Group (BMSN) To Run To 10 Cents Following Upcoming FDA Approval To Move Forward With HemaXellerate Predicts Sierra World Equity Review. That's Just The Tip Of The Iceberg, Dollarland Coming Upon Orphan Drug Designation Forecasts Sierra World Equity Review.

For the latest updates on these stocks and to learn more about Sierra go to:

Sierra's Hot Stock Website
2013 FDA Calender
Latest Clinical Trial Results

A list of all Sierra's accurate calls and predictions that came true:
All These Came True, Accurate Sierra Are You Believer Yet!!!

Accurate call after accurate call, smart, single supermodel Sierra is SMOKING HOT in her predictions!! From FDA Drug Approvals and Trials to Potential Joint Ventures, Mergers, Buyouts, Acquisitions and Lawsuit Settlements..... get THE Scoop, always on the cutting edge of BIG Breaking News. Sierra covers all sectors from Biotech to Oil stocks, Gold stocks, Penny stocks on the OTC as well as the S&P, Nasdaq, Dow Jones and Amex. Famous for her HEADLINERS, Sierra made more correct calls in the last 9 months than all other Stock Reviews COMBINED.
Check back for instant updates....Independent Sierra World Equity Review currently hold no positions in any of the stocks listed above......be the first to read Sierra's new posts, follow Sierra on Twitter
Sierra World Equity Review at 1:02 AM

BMSN $ STRONG BUY $ Target: 1,00+ US Dollars

< Message edited by Bullrider77 -- 3/2/2013 3:40:26 PM >

Mit Zitat antworten Beitrag zum Zitieren auswählen Direkt antwort
BMSN - NEWS $$$ FDA 2013 Calender and Clinical Trial Results $$$ —Alert__BREAKING>>> Beitrag #3
Daumen hoch BMSN. BMSN. BMSN. NEWS. NEWS. Big big NEWS soon IMO. SATURDAY, FEBRUARY 16, 2013

BMSN - Longterm Target. 1,00+ US$$$ Dollars

TankerOne · 14-03-2013, 01:35

http://investorshub.advfn.com/boards...ge_id=85638275

TankerOne · 18-03-2013, 18:50

BMSN - MEGA NEWS $$$ $$$ Regen BioPharma Receives IND # From FDA for HemaXellerate
Print
Alert
Bio-matrix Scientific Group, Inc. (PL) (USOTC

MSN)
Intraday Stock Chart

Today : Monday 18 March 2013
Click Here for more Bio-matrix Scientific Group, Inc. (PL) Charts.

Regen BioPharma, Inc., a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today issuance of IND number 15376 for its proposed Phase I/II clinical trial evaluating use of its stem cell product, HemaXellerate, for treatment of aplastic anemia.

As part of the clinical trial approval process, the FDA will issue comments on the proposed trial which must be addressed to the FDA's satisfaction before patient dosing is initiated. The clinical trial will treat ten patients with aplastic anemia that have not responded to conventional therapy and lack a bone marrow donor.

"We are pleased that the company has been issued an IND number and has taken the first step towards regulatory approval in the USA," said David Koos, Chairman & CEO of Bio-Matrix. "We have compiled an internationally-renowned team, consisting of corporate and academic partners, which cover the manufacturing, regulatory, and medical aspects of the project. Members of the team have previously published with Regen the scientific rational for the trial in a peer-reviewed publication in January of last year which may be found at http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf."

HemaXellerate is a patient-specific composition of cells that have previously been demonstrated to repair damaged bone marrow and stimulate production of blood cells based on previous animal studies. If the clinical trial is successful, the company plans to expand use of HemaXellerate™ to other conditions associated with bone marrow dysfunction, with the overall goal of entering the hematopoietic growth factor market. This market is substantial in size and currently includes drugs such as Neupogen®, Neulasta®, Leukine® and Revolade®.

About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:

Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN) through its wholly owned subsidiary, Regen BioPharma, Inc., is a biotechnology company focused on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials. To follow our development, visit us at www.regenbiopharma.com.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact:

Bio-Matrix Scientific Group, Inc. and
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
619-702-1404
www.regenbiopharma.com